Capricor Therapeutics, Inc. (CAPR) - Stock Analysis
Last updated: Apr 4, 2026
Research Idea
Research content for general circulation. Not individualized advice.Ā Methodology & Disclosures
High-risk regulatory/event play: FDA has resumed review of Capricor's BLA for Deramiocel after a Class 2 resubmission (PDUFA 2026-08-22), and management has flagged an imminent HOPEā3 top-line readout. The stock rallied ~24% over 21 days on this setup; with clear dated catalysts and recent institutional interest, trading into/around the HOPEā3 data window offers asymmetric near-term upside (balanced by binary trial and financing risk).
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ā¢ Large cash reserve ā¢ Zero revenue ā¢ High R&D burn CAPR has a strong cash position and low leverage but no revenue and large R&D-driven operating losses producing persistent negative cash flow and profitability. #no-revenueā #cash-cushionā
Price Behavior
Key Price Behavior Insights: ā¢ Strong momentum ā¢ Compressed resistance ā¢ Elevated volatility Support Level: $30.10ā$30.60 Resistance Level: $33.40ā$33.60 Over the last month CAPR rallied ~24% from $25.82 to $32.11 showing strong momentum with higher highs/lows, clear resistance at $33.40ā$33.60 and near-term support at $30.10ā$30.60, while elevated volatility (gap to $33.42 and retrace to $27.77) increases both upside and downside risk.
Sentiment & News
Key News Insights: ā¢ Regulatory clarity ā¢ Positive HOPE-3 ā¢ Earnings miss/insiders Capricor regained regulatory momentumāFDA resumed its BLA review with an Aug 22 PDUFA after HOPEā3 data, but a Q4 miss and insider sales dampened the rally.
AI Summary
CAPR has shifted into a nearāterm binary investment: Deramiocel's FDA resumption makes the PDUFA timing and HOPEā3 functional readout the dominant value drivers that will likely crystallize most upside on approval or materially increase financing/dilution risk if delayed. Actionable triggers to watch now are the PDUFA date, HOPEā3 alpha outcome and FDA feedback, plus receipt (or not) of the ~$80M NS Pharma milestone since cash runway (~12ā18 months absent proceeds) makes timing the key determinant of equity value.
Description
Capricor Therapeutics is a clinical-stage biotechnology company developing cell- and exosome-based therapies for a range of diseases. Its lead candidate, CAP-1002, has completed a Phase III trial in late-stage Duchenne muscular dystrophy and is in Phase II testing for SARSāCoVā2ārelated cytokine storm; the pipeline also includes a preclinical program for trauma-related injuries and vaccine candidates targeting COVIDā19. The company outsources clinical manufacturing of CAP-1002 to Lonza Houston, was founded in 2005, and is based in San Diego, California.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Mar 10 | Mar 17 | CAPR | Capricor Therapeutics, Inc. | High-risk regulatory/event play: FDA has resumed review of Capricor's BLA for Deramiocel after a Class 2 resubmission (PDUFA 2026-08-22), and management has flagged an imminent HOPEā3 top-line readout. The stock rallied ~24% over 21 days on this setup; with clear dated catalysts and recent institutional interest, trading into/around the HOPEā3 data window offers asymmetric near-term upside (balanced by binary trial and financing risk). | Closed | -6.6% |